Ergomed Sustainability Profile
Ergomed plc, a leading provider of specialised services to the pharmaceutical industry, is headquartered in Great Britain. Founded in 1997, the company has established a strong presence in key operational regions, including Europe and North America. Ergomed focuses on two main business areas: drug development and post-marketing services, offering a unique blend of expertise that enhances the efficiency of clinical trials. With a commitment to quality and innovation, Ergomed provides a range of core services, including clinical research, pharmacovigilance, and regulatory affairs. The company has achieved notable milestones, such as its successful listing on the London Stock Exchange, solidifying its position as a trusted partner in the life sciences sector. Ergomed's dedication to tailored solutions and client satisfaction sets it apart in a competitive market.
DitchCarbon Score
How does Ergomed's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ergomed's score of 32 is higher than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Ergomed's reported carbon emissions
In 2022, Ergomed reported total carbon emissions of approximately 46,150 kg CO2e. This figure includes Scope 1 emissions of about 730 kg CO2e, primarily from stationary combustion, and Scope 2 emissions of approximately 14,290 kg CO2e from purchased electricity. Notably, Scope 3 emissions accounted for a significant portion, with about 17,290 kg CO2e from business travel and approximately 18,980 kg CO2e from upstream transportation and distribution. Comparatively, in 2021, Ergomed's total emissions were about 60,640 kg CO2e, with Scope 1 emissions at 60 kg CO2e and Scope 2 emissions at approximately 25,450 kg CO2e. The Scope 3 emissions for that year were around 17,530 kg CO2e from business travel and about 26,210 kg CO2e from upstream transportation and distribution. This indicates a reduction in total emissions of approximately 14,490 kg CO2e from 2021 to 2022. Ergomed has not set specific reduction targets or climate pledges, and there are no emissions data cascaded from a parent organization. The company is committed to monitoring and reporting its emissions, as evidenced by its disclosures, but lacks formalised reduction initiatives or targets at this time.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | |
|---|---|---|
| Scope 1 | 60 | 000 |
| Scope 2 | 25,450 | 00,000 |
| Scope 3 | 43,740 | 00,000 |
How Carbon Intensive is Ergomed's Industry?
How Carbon Intensive is Ergomed's Location?
Ergomed's Scope 3 Categories Breakdown
Ergomed's Scope 3 emissions, which decreased by 17% last year and decreased by approximately 17% since 2021, demonstrating supply chain emissions tracking. Most of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 71% of total emissions under the GHG Protocol, with "Upstream Transportation & Distribution" being the largest emissions source at 52% of Scope 3 emissions.
Top Scope 3 Categories
Ergomed's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Ergomed has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
